about
Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progressionAcute high-altitude exposure reduces lung diffusion: data from the HIGHCARE Alps project.Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry.High-altitude hypoxia and periodic breathing during sleep: gender-related differences.Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial.Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project.Effects of slow deep breathing at high altitude on oxygen saturation, pulmonary and systemic hemodynamicsGenetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy.European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring.Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations.European Society of Hypertension practice guidelines for home blood pressure monitoring.Diastolic dysfunction in controlled hypertensive patients with mild-moderate obstructive sleep apnea.Role of birth weight and postnatal growth on pulse wave velocity in teenagers.Ischemic changes in exercise ECG in a hypertensive subject acutely exposed to high altitude. Possible role of a high-altitude induced imbalance in myocardial oxygen supply-demand.Disappearance of isocapnic buffering period during increasing work rate exercise at high altitude.Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.Regional abnormalities of myocardial deformation in patients with hypertrophic cardiomyopathy: correlations with delayed enhancement in cardiac magnetic resonance.Changes in 24 h ambulatory blood pressure and effects of angiotensin II receptor blockade during acute and prolonged high-altitude exposure: a randomized clinical trialChanges in subendocardial viability ratio with acute high-altitude exposure and protective role of acetazolamideEffects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposureEffects of beta-blockade on exercise performance at high altitude: a randomized, placebo-controlled trial comparing the efficacy of nebivolol versus carvedilol in healthy subjectsModulation of urinary peptidome in humans exposed to high altitude hypoxiaIndex measured at an intermediate altitude to predict impending acute mountain sicknessHigh-altitude exposure of three weeks duration increases lung diffusing capacity in humansEffects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitudeContinuous positive airway pressure increases haemoglobin O2 saturation after acute but not prolonged altitude exposureInformation on arterial properties from home blood pressure monitoring: work still in progressHome blood pressure telemonitoring improves hypertension control in general practice. The TeleBPCare studyObtaining arterial stiffness indices from simple arm cuff measurements: the holy grail?Long term vagal stimulation in patients with advanced heart failure First experience in manGenetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure
P50
Q28235380-EE2CFEB7-1522-49C7-84C6-968AED6E84F3Q30619949-9F21544B-E2D2-48C9-AE81-FEC49D6AF0E5Q31085984-AF73CAE3-FFBD-4E64-8EA0-726444F24C9CQ33456807-90EAEFA7-7E02-4D45-9780-03923E23F778Q33554096-E93CB2E1-E0D9-4D9C-ACE9-6BE732202168Q33768376-0B06FF17-A74F-4283-8ED8-B24E6EFBE82DQ34477709-D89E1166-00FC-450D-9A80-05BC020B947AQ36773270-E2DE5DF8-13AA-41B7-AEBB-5183ABB8A1F7Q37214481-4DC43BE7-782E-412D-95DC-CB8275526D92Q37413343-7890599C-DEF2-4356-8207-1173AE3415D3Q37762443-6644B83D-4765-40D3-88BD-A28DE96F539FQ41017349-562881F6-8B81-4C93-A8B0-18A539DD25E6Q44662974-06BF90C6-607B-48FA-8DE3-9A809A773EA5Q45810084-8753090A-F557-4324-8420-9DEE1DAC8437Q46558373-3C25742F-0162-4B17-A8AD-2ECE74DE941BQ46888862-4BFFD087-5F8B-45AE-865F-54693C7CFEE0Q53331561-E20F04A3-BB34-4479-8A41-08245FEAAAC0Q57095934-1C61C7BD-405E-479B-9438-3AC0BE39EDD8Q57097697-9DA90DB7-748B-4376-90E0-D237CC96F8C8Q57097762-B6611AE1-1774-45E4-9613-A97D9801414DQ57098602-F656B409-ED25-4932-9DFB-52DBCDA6713FQ57099063-15A25FD2-7A18-4F47-8A01-B81809E1A642Q57100026-F8447F6C-5142-4772-A443-69EEE1BC9C66Q57100378-2D83CB39-DCD9-4301-8C03-B12AC9AC341AQ57100784-922E4B46-8468-4278-ABE0-DDCF36C49D28Q57101837-F7A1C948-3396-4071-B8F8-CAC58E77F6B5Q57487895-E105EB26-469F-421B-A80A-8ECAA7AF7523Q57488047-E03DC2ED-8D03-43A4-88F5-C468174F3368Q57488087-C0D7CE36-1A55-4DB5-8072-9767F2A582D8Q58010727-E8D40BFC-8C85-4B6D-8167-71FC7D592595Q58319592-99D56711-5433-4F8D-AAD2-0623AF2DBDD1
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Miriam Revera
@ast
Miriam Revera
@en
Miriam Revera
@es
Miriam Revera
@nl
type
label
Miriam Revera
@ast
Miriam Revera
@en
Miriam Revera
@es
Miriam Revera
@nl
prefLabel
Miriam Revera
@ast
Miriam Revera
@en
Miriam Revera
@es
Miriam Revera
@nl
P106
P21
P31
P496
0000-0002-3388-1858